News | Cath Lab | May 16, 2017

Early Treatment for NSTEMI Patients Shows Greater Rate of Survival

First time an analysis demonstrates reduction in mortality between early and late intervention

Early Treatment for NSTEMI Patients Shows Greater Rate of Survival

May 16, 2017 — An analysis of non ST-elevation myocardial infarction (NSTEMI) patients who undergo coronary revascularization within 24 hours of hospitalization showed an increased reduction in mortality, marking the first time this difference has been demonstrated. Results from “Outcomes of Early vs. Late Revascularization in Low and High-Risk Patients Hospitalized with Non-ST-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Surveillance Study” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

NSTEMI is a type of heart attack that occurs when an artery is only partially blocked as opposed to a STEMI, where there is a complete blockage of the artery, making it the more severe of the two types.

While current guidelines recommend early intervention — defined as less than 24 hours — for STEMI patients, a delayed or late strategy — defined as between 24–72 hours — for NSTEMI is considered reasonable, unless there are extenuating circumstances, such as refractory angina or other conditions that put the patient in a higher risk category.

However, the optimum time for coronary revascularization of NSTEMI patients is under debate, according to Sameer Arora, M.D., of the University of North Carolina at Chapel Hill, Division of Cardiology and the study’s lead investigator. Evidence for current recommendations is based on clinical trials in controlled settings and selected patients.

Arora and his collaborators looked at data from the ARIC Community Surveillance Study, a large, ongoing investigation that began in 1987 involving 21 hospitals in four states: Maryland, Minnesota, Mississippi and North Carolina. Arora analyzed data from hospitalized NSTEMI patients undergoing coronary revascularization, and classified them as low- or high-risk, based on accepted risk scores. The survival benefit of an early revascularization (<24 hours after symptoms start) versus a late revascularization was analyzed using statistical models.

From 1987–2012, 9,960 patients were hospitalized with NSTEMI and underwent revascularization (67 percent percutaneous intervention, 28 percent bypass surgery and 5 percent thrombosis). Most were white (81 percent), male (69 percent), with a mean age of 62; approximately half (54 percent) were classified as low-risk. The overall 28-day mortality was 3 percent and most revascularizations (66 percent) were late.

After adjusting for confounding variables, such as diabetes and hypertension among others, early intervention was associated with an 87 percent lower mortality for low-risk patients (OR = 0.13; 95 percent CI: 0.02 – 0.93; p=0.04) and a 38 percent lower mortality for high-risk patients (OR = 0.62; 95 percent CI: 0.40 – 0.94; p=0.04). The association was consistent regardless of sex, race, or year of hospitalization.

Arora noted, “What we observed was both low- and high-risk NSTEMI patients who were treated within 24 hours of symptom onset had a 28-day survival benefit. To our knowledge, no clinical trials to date have reported a survival benefit related to early versus late revascularization.”

Arora reported no disclosures.

For more information: www.scaiscientificsessions.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init